Impact of Onco-sexology Support on the Quality of Life of Patients Newly Diagnosed for Cancer
Condition(s) studied
Investigational drug(s) / intervention(s)
Onco-sexology support: Initiation of onco-sexology support before the introduction of systemic oncology treatment
Onco-sexology support: Initiation of onco-sexology support after the introduction of systemic oncology treatment (2-3 months after the start of treatment).
Study summary
Onco-sexology as a supportive care for patients treated for cancer is still rarely discussed or even non-existent in 2022. However, it's recommended to integrate the preservation of sexual health throughout the treatment and post-cancer process, given the impact of cancer, treatments and the importance of intimate life for a majority of patients.
Onco-sexology is one of the supportive care services validated by The French National Cancer Institute (INCa). It is also an objective of the 2014-2019 cancer plan and the 2017-2030 national sexual health strategy plan.
Although sexuality is one of the fundamental needs of the human being, including in the case of a chronic disease or cancer diagnosis, the lack of training of health professionals to deal with intimate life, the difficulty to exchange on this subject between caregivers and patients, the lack of financial support for onco-sexology consultations, are all obstacles to the global management of oncology patients. However, it's a request from patients to be able to discuss the subject in an intimate way with a professional.
While onco-sexology is already recommended as supportive care, a study on the impact of the delay in the management of sexual difficulties on quality of life could provide a sufficient level of evidence to change the practices and the care pathway of the oncology patient. Our objective is to study whether early management in onco-sexology has an impact on quality of life compared to late management (ie onco-sexology consultation before vs. after introduction of systemic oncological treatment).
Eligibility
Primary outcome measure(s)
- Rate of patients with improved quality of life as measured by the 36-Item Short Form Survey (SF-36) at the end of onco-sexology support — 4 months
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Hôpital Européen Marseille | Marseille | France | Recruiting |
More Hôpital Européen Marseille trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06332573 on ClinicalTrials.gov ↗ ← All trials in France